| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CYSTIC FIBROSIS |
Department of Respiratory Medicine, Royal Brompton Hospital, London SW3 6NP, UK
Correspondence to:
Correspondence to:
Professor D Geddes
Respiratory Medicine, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK; d.geddes{at}rbh.nthames.nhs.uk
Background: CF is characterised by a progressive decline in lung function; reductions in this decline are often used as a measure of success in clinical trials. With improvements in treatment it may be that there has been a temporal shift in the pattern of the disease.
Methods: 318 patients born in five successive cohorts and attending a specialist clinic with at least two routine measurements of lung function made between the ages of 18 and 22 were included. The declines in their lung function were estimated and compared.
Results: The mean (SE) slopes for percentage predicted forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were –1.53 (0.36)% and –1.27 (0.34)%, respectively (NS). The annual deterioration in FEV1 was –2.49%, –1.99% –2.20%, –1.65%, and –0.65% from the earliest to the most recent birth cohort; a similar pattern was observed for changes in FVC. There were no differences between male and female patients. Patients infected with Pseudomonas had a greater average decline in FEV1 (–1.6% v –1.1%).
Conclusions: The rates of decline in lung function in young adults with CF have diminished with successive birth cohorts. This has important implications for the design of clinical studies in this disease.
Keywords: cystic fibrosis; lung function; young adults
Relevant Article
Thorax 2006 61: 93.
This article has been cited by other articles:
|
|
 |
|
  J. C Davies, S. Cunningham, E. W F W Alton, and J A Innes Lung clearance index in CF: a sensitive marker of lung disease severity Thorax, February 1, 2008; 63(2): 96 - 97. [Full Text] [PDF]
|
|
|
|
|
|
A R Horsley, P M Gustafsson, K A Macleod, C Saunders, A P Greening, D J Porteous, J C Davies, S Cunningham, E W F W Alton, and J A Innes Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis Thorax, February 1, 2008; 63(2): 135 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Corey Power Considerations for Studies of Lung Function in Cystic Fibrosis Proceedings of the ATS, August 1, 2007; 4(4): 334 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. W. M. Tiddens and P. A. de Jong Imaging and Clinical Trials in Cystic Fibrosis Proceedings of the ATS, August 1, 2007; 4(4): 343 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C Bell and P. J Robinson Exacerbations in cystic fibrosis: 2 {middle dot} Prevention Thorax, August 1, 2007; 62(8): 723 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Schnabel, C. Grasemann, D. Staab, H. Wollmann, F. Ratjen, and for the German Cystic Fibrosis Growth Hormone Stud A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Metabolic and Respiratory Effects of Growth Hormone in Children With Cystic Fibrosis Pediatrics, June 1, 2007; 119(6): e1230 - e1238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. W. F. W. Alton, J. C. Davies, and D. M. Geddes Biomarkers for Cystic Fibrosis: Are We Progressing? Am. J. Respir. Crit. Care Med., April 15, 2007; 175(8): 750 - 751. [Full Text] [PDF]
|
|
|
|
|
|
J S Elborn and S C Bell Pulmonary exacerbations in cystic fibrosis and bronchiectasis Thorax, April 1, 2007; 62(4): 288 - 290. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
